AmpliSeq for Illumina Comprehensive Panel is now obsolete and no longer available through MyIllumina. Please work with your Illumina Sales Account Manager or Illumina Clinical Specialist to identify the best plan of action in supporting your gene panel needs.
The AmpliSeq for Illumina Comprehensive Cancer Panel provides a targeted resequencing solution for analyzing somatic mutations across 409 genes with known associations to cancer. Key features include:
The Comprehensive Cancer Panel is part of an integrated workflow that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS) next-generation sequencing (NGS) technology, and automated analysis.
This panel detects variants within multiple cancer types, including lung, colon, breast, ovarian, melanoma, and prostate malignancies. The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| NextSeq 550 System | Samples per run: mid output: 4, high output: 12 (assumes minimum coverage of 500×) | 2 × 150 bp |
| AmpliSeq for Illumina Comprehensive Cancer Panel | AmpliSeq for Illumina Cancer Hotspot Panel v2 | |
|---|---|---|
| Assay Time | 6 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) |
| Cancer Type | Pan-Cancer, Solid Tumor | Pan-Cancer, Solid Tumor |
| Content Specifications | Full exon coverage of 409 genes associated with cancer. | Hotspot regions of 50 genes with known associations to cancer |
| Description | Somatic analysis research across pan-cancer genes. | Somatic analysis research into hotspot regions of 50 cancer-related genes. |
| Hands-On Time | < 1.5 hours | < 1.5 hours |
| Input Quantity | 1–100 ng (10 ng recommended per pool) | 1–100 ng (10 ng recommended per pool) |
| Method | Amplicon Sequencing, Targeted DNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing |
| Multiplexing | 96 dual index combinations | 96 dual index combinations |
| Specialized Sample Types | Blood, FFPE Tissue | FFPE Tissue |
| Species Category | Human | Human |
Automated Solutions for AmpliSeq for Illumina Sequencing Panels
Application Note | HTML
AmpliSeq for Illumina Comprehensive Cancer Panel Data Sheet
Data Sheet | HTML
AmpliSeq for Illumina Comprehensive Cancer Panel Gene List
product_file | EXCEL < 1 MB
NextSeq 550 amplicon sequencing solution
Application Note | PDF < 1 MB
Sample identification with the AmpliSeq for Illumina Sample ID Panel
Application Note | PDF < 1 MB
Illumina Adapter Sequences Documentation
AmpliSeq for Illumina Comprehensive Cancer Panel Reference Guide Documentation
AmpliSeq for Illumina Direct FFPE DNA Kit Reference Guide Documentation
AmpliSeq for Illumina Comprehensive Cancer Panel Consumables & Equipment Documentation
AmpliSeq for Illumina Comprehensive Cancer Panel Documentation
AmpliSeq for Illumina Comprehensive Cancer Panel Checklist Documentation
Index Adapters Pooling Guide Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
All AmpliSeq for Illumina Comprehensive Cancer Panel Support
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
Targeted panel that measures expression levels of >20,000 human RefSeq genes.
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
Targeted research panel investigating somatic and germline variants in BRCA1 and BRCA2.
